Compare BSRR & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BSRR | CBIO |
|---|---|---|
| Founded | 1977 | 2003 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 482.6M |
| IPO Year | 2001 | N/A |
| Metric | BSRR | CBIO |
|---|---|---|
| Price | $40.66 | $17.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $37.00 | $26.67 |
| AVG Volume (30 Days) | 50.4K | ★ 240.6K |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 10.28 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $3.63 | $279.20 |
| P/E Ratio | $42.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.49 | $8.72 |
| 52 Week High | $41.22 | $27.41 |
| Indicator | BSRR | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 63.41 | 42.43 |
| Support Level | $32.33 | $17.02 |
| Resistance Level | $41.22 | $19.05 |
| Average True Range (ATR) | 1.69 | 1.26 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 86.74 | 21.78 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.